Polypid Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
41.7%projected annual EPS growth
Analyst Coverage
4analysts covering
FY Revenue (est.)
$15Mnext fiscal year
FY EPS (est.)
-$0.85next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Anticipated FDA PDUFA Target Action Date | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
D-PLEX100 Surgical Site Infection (SSI) Relative Risk Reduction Annually60.0Target: Maintain >50% efficacy in real-world clinical settings
Cash and Cash Equivalents (including short-term deposits) Quarterly10.9MTarget: Secure additional capital to extend runway beyond H2 2026
Quarterly Net Loss Quarterly-7.7MTarget: Narrow loss through disciplined R&D and G&A spending
Watch Items
- FDA Acceptance of D-PLEX100 NDA SubmissionTrigger: 74-day filing review period from June 1, 2026 submissionAction: Monitor for official FDA notification of NDA acceptance and confirmation of Priority Review status.
- U.S. Commercial Partnership AgreementTrigger: Late-stage discussions finalizedAction: Track execution of a definitive licensing or co-promotion agreement to support commercial launch.
- EMA MAA SubmissionTrigger: Targeted for Q3 2026Action: Monitor completion of meetings with EMA Rapporteur/Co-Rapporteur and subsequent MAA filing.
- Cash Runway and Capital RaisingTrigger: Cash resources projected to fund operations into H2 2026Action: Evaluate financing activities, including potential equity offerings, warrant exercises, or non-dilutive partnership milestones.
Research as of 19 Jun 2026